Sinus Bradycardia Associated With Daclizumab in Liver Transplant Recipients: Report of 3 Cases

Abstract

Daclizumab is a commonly used immuno­sup­pressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of brady­cardia following its administration in orthotopic liver transplant.